Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs, such as various solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Period	PE Ratio
2022-12-31	-0.03
2023-12-31	-2.10
2024-12-31	-3.86

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SGMT	$5.60	+10.22%	0.44M
3
4
5

Sagimet Biosciences Inc. (SGMT) PE Ratio

PE Ratio Data

Get Sagimet Biosciences Inc. Data in Excel

More SGMT Financial Data